Excimer laser

ELANA® Heart Bypass Solution shows promising preliminary results in first-in-human trials

Retrieved on: 
Saturday, October 8, 2022

Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.

Key Points: 
  • Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.
  • MILAN, Oct. 8, 2022 /PRNewswire/ -- The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass Solution have been unveiled today and look promising.
  • This news marks an important landmark for the ELANA (Excimer Laser Assisted Non-Occlusive Anastomosis) Heart Bypass Solution and its developer, AMT Medical.
  • "A sutureless coronary anastomosis device like the ELANA Heart Bypass Solution could effectively facilitate minimally invasive CABG," he said.

ELANA® Heart Bypass Solution shows promising preliminary results in first-in-human trials

Retrieved on: 
Saturday, October 8, 2022

Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.

Key Points: 
  • Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.
  • ELANA Heart Bypass Solution shown to be safe and feasible in humans, with all candidates free of Major Adverse Cardiovascular Events (MACE) at post-operative day 30.
  • MILAN, Oct. 8, 2022 /PRNewswire/ -- The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass Solution have been unveiled today and look promising.
  • This news marks an important landmark for the ELANA (Excimer Laser Assisted Non-Occlusive Anastomosis) Heart Bypass Solution and its developer, AMT Medical.

Pioneering Ophthalmologist Dr. Patricia Bath Makes History as One of The First Black Women to Be Inducted into The National Inventors Hall of Fame

Retrieved on: 
Tuesday, September 21, 2021

LOS ANGELES, Sept. 21, 2021 /PRNewswire/ --

Key Points: 
  • Along with inducteeMarian Croak, Dr. Bath will be one of two Black women inventors inducted onThursday, May 5, 2022.
  • Bath and Croak will be the first Black female inventors inducted by NIHF in its nearly 50-year history.
  • "To know that my mother is part of the 2022 class of National Inventors Hall of Fame Inductees is an unbelievable honor," says Dr. Eraka Bath.
  • In 1986, Dr. Bath invented theLaserphaco Probefor cataract treatment - one of the most important surgical tools in the history of ophthalmology.

Ra Medical Systems Announces Progress with Guidewire-Compatible Catheter Design and Provides Update on Atherectomy Trial Enrollment

Retrieved on: 
Tuesday, June 29, 2021

The company also announces that enrollment in its pivotal atherectomy clinical trial with the DABRA excimer laser system is now at 62 subjects, including 42 subjects enrolled since the beginning of 2021.

Key Points: 
  • The company also announces that enrollment in its pivotal atherectomy clinical trial with the DABRA excimer laser system is now at 62 subjects, including 42 subjects enrolled since the beginning of 2021.
  • Also, the current pace of enrollment in our atherectomy trial is encouraging, as we believe regulatory clearance for this indication will better position Ra Medical to address the large and growing market for treating vascular disease.
  • Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases.
  • Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif.

STRATA Skin Sciences to Participate in the Oppenheimer MedTech, Tools & Diagnostics Summit

Retrieved on: 
Tuesday, May 18, 2021

b'HORSHAM, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the Company will participate in the upcoming Oppenheimer MedTech, Tools & Diagnostics Summit.\nSTRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.

Key Points: 
  • b'HORSHAM, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the Company will participate in the upcoming Oppenheimer MedTech, Tools & Diagnostics Summit.\nSTRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.
  • Its products include the XTRAC\xc2\xae excimer laser and VTRAC\xc2\xae lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.\nThe Company\xe2\x80\x99s proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone.
  • The technology is covered by multiple patents.\nSTRATA\xe2\x80\x99s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company\xe2\x80\x99s partner dermatology clinics.\n'

Ra Medical Systems Reports 2021 First Quarter Financial Results

Retrieved on: 
Tuesday, May 11, 2021

b'Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2021 and provides a business update.\n\xe2\x80\x9cI\xe2\x80\x99m pleased by our recent progress, particularly with the increased enrollment in our atherectomy pivotal study.

Key Points: 
  • b'Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2021 and provides a business update.\n\xe2\x80\x9cI\xe2\x80\x99m pleased by our recent progress, particularly with the increased enrollment in our atherectomy pivotal study.
  • We have enrolled 20 subjects since mid-March bringing total enrollment to 50, reaching the halfway point in this 100-subject study,\xe2\x80\x9d said Will McGuire, Ra Medical Systems CEO.
  • Research and development expenses for the first quarter of 2021 were $2.8 million, compared with $1.3 million for the first quarter of 2020.
  • Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif.

Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021

Retrieved on: 
Monday, May 10, 2021

b'Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases.

Key Points: 
  • b'Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases.
  • The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma.
  • DABRA and Pharos are both based on Ra Medical\xe2\x80\x99s core excimer laser technology platform and deploy similar mechanisms of action.
  • Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif.

Ra Medical Systems Provides Enrollment Update for its Pivotal Atherectomy Clinical Trial

Retrieved on: 
Tuesday, April 20, 2021

(NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces an increase in enrollment in its pivotal clinical trial to evaluate the safety and effectiveness of the DABRA excimer laser system as an atherectomy device for the treatment of peripheral arterial disease (PAD).

Key Points: 
  • (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces an increase in enrollment in its pivotal clinical trial to evaluate the safety and effectiveness of the DABRA excimer laser system as an atherectomy device for the treatment of peripheral arterial disease (PAD).
  • A total of 42 subjects have been enrolled as of April 19, 2021.\n\xe2\x80\x9cWe are encouraged by recent progress in our atherectomy trial with 12 subjects enrolled since our last update in mid-March,\xe2\x80\x9d said Will McGuire, Ra Medical Systems CEO.
  • Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif.
  • Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and potential outcome of the DABRA atherectomy clinical study.

Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021

Retrieved on: 
Monday, April 19, 2021

This announcement does not represent any change or amendment to the Company\xe2\x80\x99s financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2020.\nRa Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases.

Key Points: 
  • This announcement does not represent any change or amendment to the Company\xe2\x80\x99s financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2020.\nRa Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases.
  • The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma.
  • DABRA and Pharos are both based on Ra Medical\xe2\x80\x99s core excimer laser technology platform and deploy similar mechanisms of action.
  • Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif.

Ra Medical Systems to Participate in Upcoming Virtual Investment Conferences

Retrieved on: 
Thursday, March 11, 2021

Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in two upcoming virtual investment conferences:

Key Points: 
  • Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in two upcoming virtual investment conferences:
    33rd Annual Roth Conference being held March 15-17, 2021.
  • Ra Medical will hold virtual investor meetings.
  • Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases.
  • Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif.